(Q38170698)

30 August 2017

ALS and neuromuscular disease: in search of the Holy Grail (English)

1 reference

amyotrophic lateral sclerosis

30 August 2017

1 reference

inferred from title

neuromuscular disease

1 reference

1

Matthew C Kiernan

1 reference

30 August 2017

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

13

1 reference

30 August 2017

13-14

1 reference

30 August 2017

1

1 reference

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

Lifetime physical activity and the risk of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

Controversies and priorities in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970226-6

7 January 2021

10.1016/S1474-4422(13)70226-6

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24331786